CL2020001576A1 - Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5. - Google Patents

Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.

Info

Publication number
CL2020001576A1
CL2020001576A1 CL2020001576A CL2020001576A CL2020001576A1 CL 2020001576 A1 CL2020001576 A1 CL 2020001576A1 CL 2020001576 A CL2020001576 A CL 2020001576A CL 2020001576 A CL2020001576 A CL 2020001576A CL 2020001576 A1 CL2020001576 A1 CL 2020001576A1
Authority
CL
Chile
Prior art keywords
bicyclic heterocyclic
substituted bicyclic
prmt5 inhibitors
heterocyclic components
prmt5
Prior art date
Application number
CL2020001576A
Other languages
English (en)
Inventor
Prathap Sreedharan Nair
Ganesh Bhausaheb Gudade
Sachin Sethi
Dipak Raychand Lagad
Chetan Sanjay Pawar
Mahadeo Bhaskar Tryambake
Chaitanya Prabhakar Kulkarni
Anil Kashiram Hajare
Balasaheb Arjun Gore
Milind Dattatraya Sindkhedkar
Venkata P Palle
Rajender Kumar Kamboj
Sanjeev Anant Kulkarni
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CL2020001576A1 publication Critical patent/CL2020001576A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos heterocíclicos bicíclicos sustituidos de fórmula (I), a sales farmacéuticamente aceptables de los mismos y a composiciones farmacéuticas para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5. La invención también se refiere a métodos para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5.
CL2020001576A 2017-12-13 2020-06-11 Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5. CL2020001576A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721044886 2017-12-13
IN201821024634 2018-07-02
IN201821040029 2018-10-23

Publications (1)

Publication Number Publication Date
CL2020001576A1 true CL2020001576A1 (es) 2020-11-06

Family

ID=65036860

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001576A CL2020001576A1 (es) 2017-12-13 2020-06-11 Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.

Country Status (27)

Country Link
US (2) US11459330B2 (es)
EP (1) EP3724190B1 (es)
JP (1) JP7282778B2 (es)
CN (1) CN111712498B (es)
AU (1) AU2018385664B2 (es)
BR (1) BR112020011746A2 (es)
CA (1) CA3085259A1 (es)
CL (1) CL2020001576A1 (es)
CR (1) CR20200263A (es)
CU (1) CU24621B1 (es)
DK (1) DK3724190T3 (es)
ES (1) ES2927860T3 (es)
GE (1) GEP20227359B (es)
HR (1) HRP20221207T1 (es)
HU (1) HUE059945T2 (es)
IL (1) IL274936B2 (es)
LT (1) LT3724190T (es)
MX (1) MX2020006181A (es)
PE (1) PE20211444A1 (es)
PH (1) PH12020550881A1 (es)
PL (1) PL3724190T3 (es)
PT (1) PT3724190T (es)
RS (1) RS63623B1 (es)
SG (1) SG11202004934QA (es)
UA (1) UA126349C2 (es)
WO (1) WO2019116302A1 (es)
ZA (1) ZA202003528B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
AU2019362753A1 (en) 2018-10-05 2021-05-20 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
KR20220016194A (ko) * 2019-05-30 2022-02-08 앤젝스 파마수티컬, 인크. Prmt5 억제제로서의 헤테로시클릭 화합물
CN114026094B (zh) * 2019-06-10 2024-06-25 印度鲁宾有限公司 Prmt5抑制剂
CR20220175A (es) 2019-10-22 2022-06-21 Lupin Ltd Combinación farmacéutica de inhibidores de PRMT5
AU2020370281A1 (en) * 2019-10-25 2022-05-26 Accent Therapeutics, Inc. METTL3 modulators
AU2020394887A1 (en) 2019-12-03 2022-06-16 Lupin Limited Substituted nucleoside analogs as PRMT5 inhibitors
US20220112194A1 (en) * 2020-04-01 2022-04-14 Aligos Therapeutics, Inc. Compounds targeting prmt5
CN115697969A (zh) * 2020-04-03 2023-02-03 弗特克斯药品有限公司 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的7-或8-羟基-异喹啉和7-或8-羟基-喹啉衍生物
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
MX2023008460A (es) 2021-01-19 2023-09-12 Lupin Ltd Combinaciones farmacéuticas de inhibidores de sos1 para el tratamiento y/o prevención del cáncer.
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009574A1 (en) 2002-07-22 2004-01-29 Novartis Ag Synthesis of discodermolide
WO2005016878A2 (en) 2003-08-13 2005-02-24 Isis Pharmaceuticals, Inc. METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
US20080045521A1 (en) 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
SI2134691T1 (sl) 2007-03-08 2012-06-29 Janssen Pharmaceutica Nv Derivati kvinolina kot PARP in TANK inhibitorji
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
SG10201506608RA (en) * 2008-09-26 2015-09-29 Agency Science Tech & Res 3-deazaneplanocin derivatives
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
TWI561512B (en) 2010-06-30 2016-12-11 Fujifilm Corp Novel nicotinamide derivative or salt thereof
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
EP2744333B1 (en) 2011-08-19 2016-10-05 Glaxosmithkline Intellectual Property (No. 2) Limited Fatty acid synthase inhibitors
EP2838898B1 (en) * 2012-04-20 2017-01-18 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
EP2861604B1 (en) 2012-06-08 2017-03-01 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
WO2014008223A2 (en) 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
EP2935243B1 (en) 2012-12-21 2018-03-14 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
JP2016505597A (ja) 2012-12-21 2016-02-25 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
CA2894126A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
KR102024417B1 (ko) 2012-12-21 2019-11-07 에피자임, 인코포레이티드 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
JP6510485B2 (ja) 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Ｐｒｍｔ５インヒビターおよびそれらの使用方法
CN106488910B (zh) 2013-10-10 2020-07-31 亚瑞克西斯制药公司 Kras g12c的抑制剂
KR101898364B1 (ko) 2014-05-22 2018-09-12 에프. 호프만-라 로슈 아게 인돌린-2-온 및 1,3-다이하이드로-피롤로[3,2-c]피리딘-2-온 유도체
PE20170146A1 (es) 2014-06-25 2017-03-08 Glaxosmithkline Ip Dev Ltd Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2015200677A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034673A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
CN107278205A (zh) 2015-02-24 2017-10-20 辉瑞大药厂 用作抗癌药的取代的核苷衍生物
EP3268044A2 (en) 2015-03-11 2018-01-17 The Broad Institute Inc. Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CA3005089A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors

Also Published As

Publication number Publication date
EP3724190B1 (en) 2022-07-06
US11952380B2 (en) 2024-04-09
ES2927860T3 (es) 2022-11-11
SG11202004934QA (en) 2020-07-29
HUE059945T2 (hu) 2023-01-28
PL3724190T3 (pl) 2022-10-31
US20210163486A1 (en) 2021-06-03
CU24621B1 (es) 2022-09-08
AU2018385664A1 (en) 2020-07-02
US11459330B2 (en) 2022-10-04
IL274936B2 (en) 2023-09-01
US20220267339A1 (en) 2022-08-25
MX2020006181A (es) 2020-09-03
JP2021506793A (ja) 2021-02-22
IL274936A (en) 2020-07-30
UA126349C2 (uk) 2022-09-21
RS63623B1 (sr) 2022-10-31
PH12020550881A1 (en) 2021-04-05
CA3085259A1 (en) 2019-06-20
ZA202003528B (en) 2022-05-25
WO2019116302A1 (en) 2019-06-20
AU2018385664B2 (en) 2022-06-02
KR20200098598A (ko) 2020-08-20
IL274936B1 (en) 2023-05-01
CR20200263A (es) 2020-07-26
DK3724190T3 (da) 2022-10-10
HRP20221207T1 (hr) 2022-12-09
CN111712498B (zh) 2023-09-29
EP3724190A1 (en) 2020-10-21
PT3724190T (pt) 2022-10-03
CU20200051A7 (es) 2021-03-11
PE20211444A1 (es) 2021-08-05
JP7282778B2 (ja) 2023-05-29
BR112020011746A2 (pt) 2020-11-17
LT3724190T (lt) 2022-10-10
CN111712498A (zh) 2020-09-25
GEP20227359B (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201691302A1 (ru) Новые гетероциклические соединения
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CO2017005588A2 (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
EA201692300A1 (ru) Производные карбоксамида
CL2021003292A1 (es) Inhibidores de prmt5.